DartRC, SurrattHL, CiceroTJ, . Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med.2015;372:241–248.
2.
VolkowND, FriedenTR, HydePS, ChaSS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med.2014;370:2063–2066.
3.
MaasJ, BartonG, MaskreyV, PintoH, HollandR. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment. Drug Alcohol Depend.2013;133:494–501.
4.
MattickRP, BreenC, KimberJ, DavoliM. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev.2014;(2):CD002207.
CochranG, WooB, Lo-CiganicWH, GordonAJ, DonohueJM, GelladWF. Defining non-medical use of prescription opioids within health care claims: a systematic review. Subst Abus.2015;36:192–202.
7.
BaxterJD, ClarkRE, SamnalievM, AwehG, O'ConnellE. Adherence to buprenorphine treatment guidelines in a Medicaid program. Subst Abus.2015:36:174–182.
8.
FoxAD, ChamberlainaA, FrostT, CunninghamCO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abus.2015;36:155–160.
9.
MuellerSR, WalleyAY, CalcaterraSL, GlanzJM, BinswangerIA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus.2015;36:240–253.
10.
BagleySM, PetersonJ, ChengDM, . Overdose education and naloxone rescue kits for family members of opioid users: characteristics, motivations and naloxone use. Subst Abus.2015;36:149–154.
11.
JenkinsJA, GordonAJ. Building connections and bridging interdisciplinary leadership in addictions: 2014 AMERSA annual conference and a thank you to reviewers. Subst Abus.2015;36:131–134.
12.
GordonAJ, JenkinsJA, GalanterM. International addiction scholarship: promise, progress, and results from the annual meetings of the International Society of Addiction Medicine. Subst Abus.2015;36:129–130.
